The Biden administration will distribute 400 million nonsurgical N95 masks; a study aims to develop a questionnaire to enable gay and bisexual men to donate blood; counterfeit versions of Gilead HIV treatments were discovered in 9 states.
The White House will announce Wednesday the United States will distribute 400 million nonsurgical N95 masks sourced from the federal Strategic National Stockpile, Politico reported. It aims to make these adult-sized masks available at tens of thousands of pharmacies and health centers across the country by early February, and is still working on a similar plan for child-sized masks. The administration also launched COVIDtests.gov this week for Americans to order up to 4 free rapid tests per household. Some apartment residents ran into issues placing these orders, but an administration official said this was not widespread and orders are being prioritized for people in higher-risk areas.
As reported by The Hill, a FDA-funded study is working to develop alternatives for gay and bisexual men who wish to donate blood to replace existing restrictions. The ADVANCE study will recruit 2000 gay or bisexual men across 8 cities to test the reliability of a donor history questionnaire based on individual HIV transmission risk. If successful, the questionnaire could replace the FDA’s current deferral policy that bars men from donating blood if they have had sexual contact with another man less than 3 months prior to donation. This news comes after the American Red Cross declared its first national blood crisis.
Gilead Sciences announced that an unauthorized network of drug suppliers sold counterfeit versions of its HIV treatment over the last 2 years, totaling $250 million, Reuters reported. Gilead found 85,247 tampered with or fake bottles of its Biktarvy and Descovy treatments. As part of an investigation, fake Gilead-labeled medications were seized from 17 locations in 9 states and identified unauthorized pharmaceutical distributors involved. The company believes that it has stopped any additional counterfeit products from these distributors from reaching patients.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More